Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Por um escritor misterioso
Descrição
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
Frontiers Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor - ScienceDirect
Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
Pharmaceutics, Free Full-Text
Full article: Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
Genes, Free Full-Text
Frontiers Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
Sulfonamides as tyrosine kinase modulators – A promising class of anticancer agents - ScienceDirect
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers - Ren - 2023 - MedComm - Wiley Online Library
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers - Ren - 2023 - MedComm - Wiley Online Library
PDF) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
